☆ 4.8 Letter

Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer

CANCER CELL (2022)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have impaired antibody response to COVID-19 vaccination. A third dose of the vaccine can improve the antibody response in some CLL patients. Patients on active treatment and those recently treated with anti-CD20 therapy have lower antibody response rates.

BLOOD (2022)

添加到收藏夹

Article Oncology

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Valerie Gounant et al.

Summary: The study found that SARS-CoV-2 vaccines were effective in patients with thoracic cancer, with the majority being immunized after two doses. Administering a third vaccine dose to 1% of patients with persistently low antibody titers resulted in an 88% immunization rate.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

Sidse Ehmsen et al.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

S. Ehmsen et al.

Summary: This nationwide prospective study found that age and comorbidities are associated with adverse outcomes of SARS-CoV-2 infection in cancer patients, especially those with progressive disease being at a greater risk of fatal outcomes from COVID-19.

ACTA ONCOLOGICA (2021)

添加到收藏夹

Letter Oncology

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen et al.

CANCER CELL (2021)

添加到收藏夹

Article Oncology

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

Jianbo Tian et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer

相关参考文献

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study

导出引文

分享论文